

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

12th December 2024

Company:	Chordia Therapeutics, Inc
Representative:	Chief Executive Officer Hiroshi Miyake (Security Code: 190A TSE Growth Market)
Contact:	Chief Financial Officer Kentaro Kume

By FISCO Corporation

Notice of Distribution of Our Corporate Research Report

Kanagawa Japan

12th December 2024 – Chordia Therapeutics Inc. (Head Office: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake) announces that a corporate research report on the Company has been distributed by Fisco Corporation.

For details, please refer to the following link.

<https://cf.pfdata.fisco.jp/data/report/20241212/6680080020241212002.pdf>

About Chordia Therapeutics

Chordia is a clinical stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan, engaged in the research and development of novel therapies for cancers.

Chordia's lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research of several preclinical assets, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors. For more information, please contact our website <https://www.chorditherapeutics.com/en/>.